# Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors

> **NCT02444546** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 6 (actual)

## Conditions studied

- Childhood Astrocytoma
- Childhood Atypical Teratoid/Rhabdoid Tumor
- Diffuse Intrinsic Pontine Glioma
- Glioma
- Recurrent Childhood Anaplastic Oligodendroglioma
- Recurrent Childhood Brain Neoplasm
- Recurrent Childhood Glioblastoma
- Recurrent Childhood Medulloblastoma
- Recurrent Primitive Neuroectodermal Tumor
- Refractory Brain Neoplasm

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Sargramostim
- **BIOLOGICAL:** Wild-type Reovirus

## Key facts

- **NCT ID:** NCT02444546
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-21
- **Primary completion:** 2018-07-13
- **Final completion:** 2022-11-21
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2023-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02444546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02444546, "Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02444546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*